Pre-Open Stock Movers 06/26: (MDCA) (VXRT) (GPS) Higher; (SHIP) (SOLY) (NKE) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Argus Reiterates Buy Rating on Nike (NKE) Following 4Q
June 30, 2020 7:26 AM EDTArgus analyst John Staszak reiterated a Buy rating and $115.00 price target on Nike (NYSE: NKE) following the company's 4Q earnings report. Nike reported fiscal 4Q20 revenue and EPS that missed estimates. Revenue of $6.3 billion. the consensus estimate had called for revenue of $7.3 billion. The adjusted... More
Altimmune (ALT) Reports First Patient Dosing in Phase 1b Clinical Trial of NasoShield
June 30, 2020 7:04 AM EDTAltimmune, Inc. (NASDAQ: ALT) today announced dosing of the first patient in the Companys Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. The NasoShield program is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA), with a total potential value of $133.7 million if all options in the contract (HHSO100201600008C) are exercised.
NasoShield is the only single dose anthrax vaccine in development that is supported by BARDA, and has the potential to provide a significant improvement over the available two- and... More
